This review describes the impact of nonmedical switching of biologic therapies on US patients and providers, with a focus on switching to in-class alternatives.
Steven Hass, PhD
Advertisement
Articles by Steven Hass, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COPD Deaths Rival Heart Failure, Exceed Prostate and Breast Cancer
2
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
5